💥Just presented at PCR London Valves, with simultaneous EuroIntervention publication! Professor Ole De Backer shared the latest DurAVR® THV clinical data from 100 small annuli patients at 30 days post-implantation. Here are the highlights: ✅ DurAVR® THV delivered a favorable

#TeamAnteris shaping the future of structural heart disease care since 1998

Anteris is proud to be part of the community revolutionizing total disease management in aortic stenosis by reshaping paradigms

Excited to kick off at PCR London Valves! Today, we’re presenting the latest data from DurAVR® THV, adding to the body of evidence, and reshaping the future treatment of aortic stenosis by shifting the paradigm.

We are excited to share new clinical data at PCR London Valves next week! On Sunday, November 16 Professor Ole De Backer will present data from 100 DurAVR® THV clinical cases in small annuli. Not attending? Sign up here for clinical data updates: https://t.co/tbetZ6gykL #TAVI

At Anteris, our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. We’ve partnered with the Minneapolis Heart Institute Foundation to conduct important research into how

Anteris at TCT: PARADIGM Trial Momentum! At the TCT Conference in San Francisco, Anteris brought together global leaders for a captivating PARADIGM Trial Investigator Meeting. Vice Chairman and CEO Wayne Paterson shared our journey to redefine valve replacement therapy. Prof.

📢 PARADIGM Trial Announcement! Anteris has received US FDA approval to launch the PARADIGM Trial for the DurAVR® Transcatheter Heart Valve (THV). The head-to-head global Investigational Device Exemption (IDE) trial will evaluate the DurAVR® Transcatheter Heart Valve (THV)

Hot off the press from TCT! We are excited to announce the first patient has been enrolled in the global PARADIGM Trial! Yesterday Dr. Rishi Puri presented this important update at TCT, along with an update on DurAVR® THV clinical evidence from the EMBARK and EFS studies. The

We are excited to share the latest clinical data at TCT next week! On Monday, October 27 Dr. Rishi Puri will present data from DurAVR® THV clinical experience. Not attending? Sign up here for clinical data updates: https://t.co/MXRumBJchv #TAVI #TAVR #aorticstenosis #TCT2025

The Paradigm Shift Starts Now! Last week, we received regulatory clearance to commence the pivotal trial for the first-in-class biomimetic DurAVR® valve. The PARADIGM Trial is the first head-to-head TAVR trial of its kind. The trial will move beyond conventional endpoints of

The Paradigm Shift Starts Now! We are proud to announce a major milestone: regulatory clearance to commence the global PARADIGM Trial for our DurAVR® Transcatheter Heart Valve (THV). This pivotal study marks the beginning of a new era in the treatment of severe aortic stenosis,

New publication in EuroIntervention just released! We are pleased to share the results of a bench study on the biomimetic DurAVR® Transcatheter Heart Valve (THV). The bench study evaluated the hydrodynamic performance of the DurAVR® valve compared to commercially available THV in

How do flow patterns impact the cardiovascular system? Does valve design impact flow patterns? In this new whitepaper, we review the pathophysiology of aortic stenosis—including upstream and downstream consequences of turbulent flow—and offer hypotheses around the impacts of TAVR

Last week Dr. Ole De Backer presented a DurAVR® THV case recording to a packed room at New York Valves! The case from Rigshospitalet in Copenhagen showcased DurAVR® THV’s paradigm-shifting hemodynamic performance with a predictable and familiar balloon-expandable delivery. Unlike

Does LV mass regression post-TAVR correlate with clear differences in patient outcomes? In the 3rd and final episode of our 3-part webinar series, Studying the Clinical Impact of Restoring Native Flow with DurAVR® THV, panelists Drs. Brian Lindman, Martin Leon, Jeffrey Popma, and

This week we hosted Heart Teams from across the globe in New York City alongside the New York Valves conference for the global investigator meeting of the PARADIGM Trial. The alignment and enthusiasm from investigators and research teams have set the stage for what promises to be

We are excited to share Episode 2 of our 3-part webinar series, Studying the Clinical Impact of Restoring Native Flow with DurAVR® THV. Building on the foundation laid out in Episode 1, this session dives deeper into the upstream and downstream impacts of restoring laminar flow

DurAVR® THV is a novel biomimetic valve that aims to restore native flow in patients with aortic stenosis. In our latest webcast, a panel of experts provides insight on this new treatment option: https://t.co/novsZ9IwSa